NCT02192294View on ClinicalTrials.gov

Absolute Bioavailability Of Bosutinib

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Healthy
Interventions
DRUG

Oral Bosutinib

a single dose of 500 mg oral bosutinib

DRUG

Intravenous infusion of bosutinib

a single dose of 120 mg of bosutinib intravenous infusion (1 hour)

Trial Locations (1)

NG11 6JS

Quotient Clinical, Ruddington Fields

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02192294 - Absolute Bioavailability Of Bosutinib | Biotech Hunter | Biotech Hunter